| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure
Date of Report (Date of earliest event reported): November 16, 2026 |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update |
| 12 Nov 2026 | QUARTERLY REPORT |
| 11 Sep 2026 |
Form 4: Shenouda Maged, Chief Financial Officer
Bought 120,200 shares ($505K) · Bought 79,800 shares ($339K) |
| 11 Sep 2026 |
Form 4: Traversa Sergio, Director
Bought 100,000 shares ($418K) · Bought 100,000 shares ($410K) |
| 08 Sep 2026 |
8-K: Other Events
Dr. Raj S. Pruthi’s employment as Chief Medical Officer – Urology of Relmada Therapeutics, Inc., ended on September 3, 2026. |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance. |
| 06 Aug 2026 | QUARTERLY REPORT |
| 29 Jul 2026 | SCHEDULE 13G |
| 28 Jul 2026 |
8-K: Regulation FD Disclosure
Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company’s long-term growth and value creation. |
| 22 Jun 2026 | SCHEDULE 13G |
| 18 Jun 2026 | REGISTRATION STATEMENT |
| 09 Jun 2026 | SCHEDULE 13G |
| 28 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Name of entity as on file with the Nevada Secretary of State : RELMADA THERAPEUTICS, INC. Entity or Nevada Business Identification Number (NVID) : NV20121345551 1. Entity information Certificate to Accompany Restated Articles or Amended ... |
| 13 May 2026 | REGISTRATION STATEMENT |
| 13 May 2026 | SCHEDULE 13G/A |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a dura... |
| 12 May 2026 | QUARTERLY REPORT |
| 04 May 2026 | SCHEDULE 13G |
Loading...